The Menarini Group, an Italy-based pharmaceutical and diagnostics company, announced on Thursday that it has received marketing authorisation from the European Commission for ELZONRIS (tagraxofusp) as monotherapy intended for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
This approval follows the positive opinion received from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) and is based on the outcome of the clinical trial conducted in patients with treatment-naïve or previously-treated BPDCN.
The product has received orphan designation in Europe, and is now the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy in Europe to address this high unmet medical need.
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid